The AKT/mTOR signaling pathway has a major role in cisplatin resistance in ovarian cancer cells; LY294002, the inhibitor of PI3K/mTOR, has been shown to sensitize ovarian cancer cells to cisplatin (16). Here, AKT1 is linked to ovarian cancer.